This product is a hypoglycemic drug that can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes. Its mechanisms may include: 1. Increasing the sensitivity of peripheral tissues to insulin and increasing insulin-mediated glucose utilization; 2. Increasing the utilization of glucose by non-insulin-dependent tissues; 3. Inhibiting hepatic gluconeogenesis and reducing hepatic glucose output; 4. Inhibiting intestinal wall cells from taking up glucose; 5. Inhibiting the biosynthesis and storage of cholesterol and reducing blood triglyceride and total cholesterol levels. Unlike insulin, this product does not promote fat synthesis and has no obvious hypoglycemic effect on normal people.